Celon Pharma Valuation
Is CLN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CLN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CLN (PLN15) is trading above our estimate of fair value (PLN12.55)
Significantly Below Fair Value: CLN is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CLN?
Other financial metrics that can be useful for relative valuation.
| What is CLN's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | zł765.85m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.2x |
| Enterprise Value/EBITDA | 238.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CLN's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3x | ||
BGD Biogened | 0.7x | n/a | zł63.4m |
SLV Selvita | 3.6x | 19.8% | zł1.3b |
SVE Synthaverse | 6x | n/a | zł353.3m |
BIO BIOTON | 1.7x | n/a | zł302.2m |
CLN Celon Pharma | 3.6x | 7.0% | zł765.8m |
Price-To-Sales vs Peers: CLN is expensive based on its Price-To-Sales Ratio (3.6x) compared to the peer average (3x).
Price to Earnings Ratio vs Industry
How does CLN's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Sales vs Industry: CLN is expensive based on its Price-To-Sales Ratio (3.6x) compared to the European Pharmaceuticals industry average (3x).
Price to Sales Ratio vs Fair Ratio
What is CLN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.6x |
| Fair PS Ratio | 4x |
Price-To-Sales vs Fair Ratio: CLN is good value based on its Price-To-Sales Ratio (3.6x) compared to the estimated Fair Price-To-Sales Ratio (4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | zł15.06 | zł16.50 +9.6% | 24.4% | zł23.00 | zł12.00 | n/a | 4 |
| Apr ’25 | zł15.12 | zł16.50 +9.1% | 24.4% | zł23.00 | zł12.00 | n/a | 4 |
| Mar ’25 | zł15.08 | zł16.88 +11.9% | 23.9% | zł23.00 | zł12.00 | n/a | 4 |
| Feb ’25 | zł15.54 | zł17.38 +11.8% | 20.1% | zł23.00 | zł14.00 | n/a | 4 |
| Jan ’25 | zł15.46 | zł17.38 +12.4% | 20.1% | zł23.00 | zł14.00 | n/a | 4 |
| Dec ’24 | zł14.84 | zł17.38 +17.1% | 20.1% | zł23.00 | zł14.00 | n/a | 4 |
| Nov ’24 | zł15.18 | zł15.50 +2.1% | 9.5% | zł17.50 | zł14.00 | n/a | 3 |
| Oct ’24 | zł15.30 | zł15.50 +1.3% | 9.5% | zł17.50 | zł14.00 | n/a | 3 |
| Sep ’24 | zł15.96 | zł17.83 +11.7% | 18.4% | zł22.00 | zł14.00 | n/a | 3 |
| Aug ’24 | zł16.90 | zł17.83 +5.5% | 18.4% | zł22.00 | zł14.00 | n/a | 3 |
| Jul ’24 | zł15.50 | zł17.83 +15.1% | 18.4% | zł22.00 | zł14.00 | n/a | 3 |
| Jun ’24 | zł16.00 | zł17.83 +11.5% | 18.4% | zł22.00 | zł14.00 | n/a | 3 |
| May ’24 | zł13.90 | zł17.83 +28.3% | 18.4% | zł22.00 | zł14.00 | n/a | 3 |
| Apr ’24 | zł15.00 | zł17.83 +18.9% | 18.4% | zł22.00 | zł14.00 | zł15.12 | 3 |
| Mar ’24 | zł15.82 | zł17.83 +12.7% | 18.4% | zł22.00 | zł14.00 | zł15.08 | 3 |
| Feb ’24 | zł17.12 | zł16.83 -1.7% | 26.8% | zł22.00 | zł11.00 | zł15.54 | 3 |
| Jan ’24 | zł14.02 | zł19.75 +40.9% | 32.3% | zł28.50 | zł11.00 | zł15.46 | 4 |
| Dec ’23 | zł14.54 | zł27.55 +89.5% | 49.8% | zł48.70 | zł11.00 | zł14.84 | 4 |
| Nov ’23 | zł13.50 | zł27.55 +104.1% | 49.8% | zł48.70 | zł11.00 | zł15.18 | 4 |
| Oct ’23 | zł13.00 | zł30.92 +137.8% | 39.6% | zł48.70 | zł11.00 | zł15.30 | 5 |
| Sep ’23 | zł14.36 | zł30.92 +115.3% | 39.6% | zł48.70 | zł11.00 | zł15.96 | 5 |
| Aug ’23 | zł18.14 | zł30.92 +70.5% | 39.6% | zł48.70 | zł11.00 | zł16.90 | 5 |
| Jul ’23 | zł15.56 | zł32.32 +107.7% | 31.2% | zł48.70 | zł18.00 | zł15.50 | 5 |
| Jun ’23 | zł18.84 | zł36.12 +91.7% | 33.0% | zł49.00 | zł18.00 | zł16.00 | 5 |
| May ’23 | zł22.10 | zł40.72 +84.3% | 16.9% | zł49.00 | zł32.00 | zł13.90 | 5 |
| Apr ’23 | zł26.25 | zł40.72 +55.1% | 16.9% | zł49.00 | zł32.00 | zł15.00 | 5 |
Analyst Forecast: Target price is less than 20% higher than the current share price.